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Immunomodulatory effects of tigecycline in Balb/c mice
Tigecycline is a glycylcycline antibiotic approved by the 
FDA for the treatment of complicated infections. Despite its 
effectiveness, the FDA announced a warning of increasing 
mortality associated with its use. There is, however, no clear 
explanation for this side effect. Previous reports found a pos-
sible effect of tigecycline on leukocyte proliferation and pro-
inflammatory cytokine release. We therefore investigated 
the effect of tigecycline on the immune components and re-
sponse in Balb/c mice in vivo and in vitro. It was found that 
tigecycline enhanced lymphocyte proliferation and signifi-
cantly increased cellular infiltration within the footpad, as 
based on DTH testing, but reduced the hemagglutination 
titer. In splenocyte cultures, tigecycline suppressed spleno-
cyte proliferation with IC50 3–5 mmol L–1, significantly in-
creased IL-2 secretion and reduced IL-17 secretion in a dose 
dependent mode. In conclusion, tigecycline is safe at thera-
peutic and sub-therapeutic doses, but it could still have an 
immunomodulatory effect at higher doses. Use of higher 
doses of tigecycline requires further investigation.
Keywords: tigecycline, immunomodulation, Balb/c mice, 
biochemical effect  
Assessment of the investigational drug toxicity to the immune system is an important 
aspect in safety evaluation of pharmaceuticals, since it is very important to identify and 
evaluate the potential effects that produce immunotoxicity during drug development (1). 
Determining the mechanism of drugs’ immunotoxicity is an important issue to under-
stand the clinical relevance of the adverse effects observed. Some drugs were found to 
induce toxicity by affecting the immune cells and lymphoid organ cellularity. The US office 
of technology and FDA defined immunotoxicants as substances that negatively affect the 
quality or the quantity of the immune response including immunosuppression, immuno-
stimulation, allergy and autoimmunity (2).
Tigecycline (TGC) is a first-in-class glycylcycline; it is a 9-tert-butylglycylamido 
 derivative of minocycline with bacteriostatic and bactericidal activity on Gram-positive, 
Gram-negative and atypical mycobacteria, but not on Pseudomonas aeruginosa and Proteus 
spp. (3). The Food and Drug Administration (FDA) approved TGC in 2005 for complicated 
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infections of skin structures, intra-abdominal and community acquired pneumonia, yet 
clinicians are using it as off-label for bacteremia, diabetic foot infections and hospital ac-
quired pneumonia (4, 5). Moreover, TGC is used as an adjunctive therapy alone or in com-
binations for bacterial infections in hematological malignancies.
Due to the emergence of tetracycline resistance, TGC was rapidly approved for use in 
complicated infections. It was shown to be safe in phase II and III clinical trials with nau-
sea and vomiting as the main side effects. After that, several case reports from clinical 
centers reported hematologic alteration and bone marrow suppression (6, 7). In September 
2010, the FDA announced a black box warning for TGC due to increased risk adjusted 
mortality of 3 to 4 % compared to other regimens, and recommended its use only when 
other alternatives were not applicable (8).
Due to the wide application of TGC, investigation of a drug’s toxicity to the immune 
system is a standard part of general toxicity studies. Previous studies showed harmful 
effects of TGC on the immune system. It was found to penetrate neutrophils and stimulate 
their proliferation and cytotoxicity by acting as a calcium ionophore, thus augmenting the 
innate response (9). However, it could have a suppressive effect on antibodies produced by 
lymphocytes (10). 
Cellular and humoral toxicity of TGC may vary according to the type of the present 
antigen. In in vivo and ex vivo murine models, T-helper (Th)-1 cytokines, but not Th-2 cyto-
kines, were suppressed (11, 12). Inhibition of T-cell proliferation was seen when TGC was 
co-cultured with S. aureus antigen (13) but not with endotoxin lipopolysaccharide (LPS) 
(14). Despite its inhibitory activity on Th-1, it did not affect production of Th-2 dependent 
antibodies in B cells (11). Conflicting results of previous researches highlight the need of 
investigating how tigecycline affects the immune system and its components.
Determining how TGC exerts its immunotoxicity is an important issue to understand 
the clinical relevance of the observed adverse effects. There are no previous studies that 
evaluated direct effects of TGC on B-lymphocytes and antibody production. The current 
study is aimed at evaluating the metabolic and immunomodulatory activities of tigecy-
cline in vitro and in vivo using Balb/c model mice.
EXPERIMENTAL
Animals
Twenty eight pathogen-free female Balb/c mice (8–10 weeks old, 19–28 g body mass) 
were purchased from the animal house of the Applied Science University (Amman, Jor-
dan) and housed in polystyrene cages in an air controlled room. All animals were main-
tained at a laboratory diet and tap water ad libitum and were acclimatized for one week 
before the experiment (15). The experiments were conducted according to the principles 
given in the guide for the care and use of laboratory animals (16). Ethical approval for 
conducting animal studies was obtained from the Ethical and Graduate Studies Council 
of the Faculty of Pharmacy at the University of Jordan (Amman, Jordan).
Materials and reagents
Tigecyl® 500 mg vials were purchased from Hikma Pharmaceuticals (Jordan). Tetra-
zolium salt, 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) powder, 
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concanavalin A (Con A), 2-mercaptoethanol (2-ME), bovine serum albumin (BSA) and 
RPMI-1640 were purchased from Sigma-Aldrich (Germany). Fetal bovine serum (FBS), 
penicillin and streptomycin, non-essential amino acids (NEAA) and sodium pyruvate so-
lution were purchased from Euroclone, USA.
Drug preparation, dose and exposure schedules
A Tigecyl® 500 mg vial was dissolved in normal saline (NS) to a concentration of 0.5 
mg mL–1 and kept at –80 °C until use. Human therapeutic dosing regimen of tigecycline is 
100 mg i.v. as a loading dose, then 50 mg i.v. twice daily for 14–21 days (17). Mice were di-
vided into four groups (I-IV) of seven animals each. Group I (control group) received NS 
by i.p. injection and groups II–IV were treated with TGC at doses of 178.6, 714.3 and 1428 
µg kg–1 bm corresponding to 0.25-, 1- and 2-times the human therapeutic dose. Each group 
received a loading dose of 0.5X, 2X and 4X, respectively, on the first day of dosing, then 
was maintained on 0.25X, 1X and 2X, resp., twice daily for 20 days by i.p. injection.
Body and metabolic organs masses
Experimental animals were weighed at the beginning of the experiment and just be-
fore the excision. Changes in body mass were recorded. At the end of the experiment, 
livers and kidneys were extracted and weighed. The mean mass of each group was com-
pared to the mean mass of the control group.
Determination of white blood cell (WBC) indices
Before excision, blood (0.2 mL) was collected from the retro-orbital plexus under light 
anesthesia from each mouse in sterile heparin tubes (Minicollect®, China) using heparin-
ized capillaries, so that the blood to anticoagulant ratio was 1:0.075, V/V. WBC count was 
determined by diluting 25 µL of EDTA blood with 475 µL of 10 % acetic acid. Cells were 
counted using a hemocytometer (18). For differential leukocyte count, a blood film was 
stained with Gimsa and Wright for each treated animal and counted under a light micro-
scope (Nikon, China) at 100X.
Biochemical markers of acute liver and kidney injuries
Blood was collected in sterile plain tubes and left at room temperature for 2 h before 
serum was separated. Serum was stored at –20 °C for later use to measure alanine trans-
aminase (ALT), aspartate transaminase (AST), serum creatinine (Scr) and urea using Alfa 
Wassermann diagnostic kits (USA).
Spleen cellularity assay
Single cell suspension of splenocytes was prepared according to Fararjeh et al. (19) with 
some modifications. Spleens collected from mice were teased in PBS using frosted-edge mi-
croscopic slides to remove connective tissue. The suspension was centrifuged at 1600 rpm for 
7 min. RBCs present in the suspension were lysed at room temperature with RBC lysing 
buffer (0.83 % NH4Cl in 0.0178 mol L–1 NaHCO3 and 0.127 mmol L–1 EDTA, adjusted pH 7.4), 
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then washed with PBS three times. The pellets were re-suspended in PBS and cells were 
counted using a hemocytometer under the light microscope. The mean difference in the 
splenocyte count was analyzed using one-way ANOVA on Graphpad Prism 6.
Delayed type hypersensitivity
Delayed-type hypersensitivity response (DTH) was determined using the method of 
Fararjeh et al. (19) with some modifications. On day 14 of the treatment, animals were in-
jected subcutaneously with 1 × 109 sheep red blood cells (SRBCs) into the ventral flank. 
After five days of immunization (day 19), all animals were again challenged with a booster 
dose of 1 × 108 per 10 µL SRBCs in the left hind footpad. The right hind footpad was injected 
with the same volume of PBS to serve as trauma control for nonspecific swelling (19). The 
change in the left footpad volume was measured as the difference between SRBC-injected 
and PBS-injected hind footpad volumes 24 hours after the challenge with SRBCs. The dif-
ference between the left and right hind footpad volumes was calculated using a digital 
plethysmometer LE 7500 (Harvard, UK).
Hemagglutination assay
Five days before ending the treatment (day 15), mice were injected i.p. with 5 × 108 
SRBCs in PBS. At the end of experiment (day 20), blood was collected from the retro-orbital 
plexus of each mouse before being sacrificed, where serum was separated and serially 
diluted in duplicates in PBS and placed in the wells of U-shape 96-microtiter plates. Ali-
quots (25 µL) of two-fold diluted sera in PBS were challenged with 25 µL of 1 % V/V SRBCs 
suspension and mixed. The plates were incubated at 37 °C for 1 h and then observed for 
hemagglutination. The log2 of the highest dilution giving hemagglutination was taken as 
the antibody titer (18).
In vitro tigecycline cytotoxicity and cytokine response: Splenocyte culture preparation
Spleens from two female pathogen-free untreated Balb/c mice, aged 6–8 weeks, were 
extracted under sterile conditions and transferred to 15 mL of PBS in a 10-cm Petri dish. 
Single cell suspension of splenocytes was prepared as described in the spleen cellularity 
assay. Cultures were finally prepared using complete RPMI-1640 (cRPMI-1640) composed 
of 10 % FBS, 1 % penicillin-streptomycin, 1 mmol L–1 sodium pyruvate, 1X NEAA and 0.05 
mmol L–1 of 2-ME.
Determination of tigecycline cytotoxicity
Splenocyte density was adjusted to 3 × 106 cell per 100 µL in cRPMI-1640 medium and 
placed in each well of a 96-well microtiter plate. An aliquot of 100 µL of TGC diluted in 
cRPMI-1640 to a concentration of 200 to 0.1 µmol L–1 was added and incubated for 48 h at 
37 °C (95 % humidity and 5 % CO2). Two sets of plates were prepared; one was pretreated 
with 2 µg mL–1 Con A mitogen while the other was left without mitogen. A MTT assay was 
done at the end of each treatment interval to determine cell viability. To each well, 20 µL 
of 5 mg mL–1 MTT solution was added and the plates were incubated for 4 hours. Precipi-
tated formazan crystals were dissolved in 200 µL DMSO and absorbance was measured at 
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570 nm/630 nm using a plate reader (Biorad, Japan). In this experiment, three wells were 
used for each concentration of TGC in the assigned concentration range (0.1–200 µmol L–1). 
The whole experiment was repeated twice.
In vitro determination of cytokine release from splenocytes
Splenocyte count was adjusted to 5 × 106 mL–1 in cRPMI-1640 medium containing 1 % 
(V/V) mouse serum (cRPMI – 1 % mS). One milliliter of cell suspension was transferred to 
each well in a 24-well plate and incubated for 30 min at 37 °C (5 % CO2 and 90 % humidity). 
Two-fold serial dilution of the drug was prepared (12.5 to 0.195 µmol L–1) in cRPMI – 1 % 
mS and added to each well. Cells were pretreated with 2 µg mL–1 Con A. After 72 h, the 
supernatant was collected, aliquoted and stored at –20 °C for later use. Murine interleukin 
(IL)-17 and IL-2 cytokines were measured using the ELISA assay according to the manu-
facturers’ protocol (R&D Systems, USA and eBioscience, UK, resp.). All cytokine assays 
were calibrated against WHO standards using the manufacturer’s kit. 
Statistical analysis
Data were presented as mean ± SD of the indicated number of experiments. Statistical 
analysis was done using one-way analysis of variance (ANOVA) followed by Dunnett’s 
post-hoc test to check for significant differences. A difference was considered significant 
at p < 0.05. All analyses were made using the GraphPad Prism 6 statistical software pack-
age.
RESULTS AND DISCUSSION
For direct immunotoxicity effect of tigecycline in vivo, we investigated its effect on the 
total body mass, liver and kidney masses, spleen cellularity, differential WBCs, delayed 
type hypersensitivity and hemagglutination.
Body and metabolic organs’ masses
As alteration of body mass and internal organs’ mass is a primary sign of immuno-
toxicity, mean body masses were determined before and after the treatment as well as 
absolute liver and kidney masses (Table I). Tigecycline caused no significant change in the 
total body mass with three different doses compared to the control group (Table I). Our 
results are in line with the results obtained from retrospective studies and animal models 
that showed body mass of healthy animals maintained upon treatment with parent com-
pounds (20).
Biochemical markers of acute liver and kidney injuries
As TGC is eliminated mainly by hepatic metabolism via glucuronidation and to a 
limited extent by renal excretion, we investigated the changes in liver and kidney func-
tions after the treatments. Groups treated with TGC showed no significant change in ALT 
and AST liver enzymes, which are reasonably sensitive indicators of acute liver damage or 
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injury (Table II). Kidney function tests showed no significant changes upon treatment with 
TGC. This is consistent with pharmacokinetic studies and case reports of its use in acute 
kidney injury because of urosepsis (21, 22) and might indicate that the drug is not toxic to 
liver or kidneys.
Table I. The effect of tigecycline on terminal body mass and absolute organ masses of mice 
Treatment 
group
Initial body mass 
(g)a
Terminal body 
mass (g)a Liver (g)
a Kidney (g)a
Control (NS) 22.29 ± 2.36 24.14 ± 1.22 1.00 ± 0.16 0.23 ± 0.04
0.25X 22.43 ± 2.94 23.14 ± 2.12 1.25 ± 0.24 0.25 ± 0.04
1X 21.71 ± 1.70 22.00 ± 2.31 1.21 ± 0.30 0.25 ± 0.04
2X 23.86 ± 3.13 23.43 ± 2.37 1.07 ± 0.12 0.24 ± 0.03
NS – normal saline; 0.25X – 12.5 mg per 70 kg per dose; 1X – 50 mg per 70 kg per dose; 2X – 100 mg per 70 kg per 
dose; a Mean ± SD, n = 7.
Table II. The effect of TGC on liver and kidney functions of mice 
Treatment group Urea (mg per 100 mL)a
Serum creatinine 





Control (NS) 49.80 ± 10.01 0.69 ± 0.34 57.00 ± 16.90 234 ± 61
0.25X 64.14 ± 12.58 0.77 ± 0.35 67.50 ± 13.16 268 ± 55
1X 52.50 ± 10.13 0.83 ± 0.16 60.00 ± 10.50 283 ± 50
2X 55.36 ± 12.82 0.66 ± 0.28 72.70± 39.79 253 ± 44
ALT – alanine aminotransferase, AST – aspartate aminotransferase, NS – normal saline; For doses see Table I. a 
Mean ± SD, n = 7.











Control (NS) (9.50 ± 0.55)x103 8.09 ±1.16 78.27 ± 1.51 12.09 ± 1.34
0.25X (9.40 ± 0.74) x103 8.90± 1.75 80.70 ± 3.31 9.40 ±1.78
1X (10.83 ± 0.96) x103 10.27 ± 2.05 76.10 ± 4.05 13.36 ± 2.36
2X (10.80 ±0.94) x103 11.20 ± 2.47 74.80 ± 4.52 12.60 ±2.83
NS – normal saline, WBC – white blood cells; For doses see Table I; a Mean ± SD, n = 7.
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Fig. 1. Spleen cellularity in vivo after treatment with 0.25X, 1X and 2X tigecycline or NS (control) for 
20 days via i.p. injection. Cell count is expressed as mean ± SD, n = 7; NS – normal saline; 0.25X – 12.5 
mg per 70 kg per dose; 1X – 50 mg per 70 kg per dose; 2X – 100 mg per 70 kg per dose.
Fig. 2. The effect of tigecycline on delayed type hypersensitivity (DTH) measured as the change in 
footpad volume. Data are mean ± SD, n = 7. Significant difference versus control animals (NS): *p < 0.05; 
NS – normal saline; for dosing see Fig. 1.
White blood cell indices
Leukocytosis and/or leucopenia are other rare side-effects (less than 1 %) of TGC. 
Preclinical studies in rats, dogs and monkeys indicated the safety of TGC for blood cells 
(4) and so did our results. Tigecycline slightly increased the WBC count and percentage of 
peripheral blood neutrophils and monocytes at therapeutic (1X) and toxic doses (2X), but 
not significantly (Table III). Although TGC did not significantly change the WBC count or 
relative counts of neutrophils, lymphocytes and monocytes in vivo, it showed a slight in-
crease in relative neutrophil counts with a slight decrease in relative lymphocyte count in 
a dose-dependent manner. Unlike macrolides that accelerate neutrophil apoptosis and 
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impair neutrophil migration (23), a previous study showed that TGC penetrates neutro-
phils and maintains their intracellular concentration for a relatively long time. Besides, it 
enhances the proliferation and proinflammatory activities of neutrophils in vitro (9).
Spleen cellularity
Spleen is a secondary lymphoid organ where B cells mature to become plasma cells 
that produce antibodies. Immunotoxic drugs affect B lymphocytes by altering spleen’s cel-
lular structure and lymphocyte function. TGC has been reported to show a variety of 
immunotoxic effects, such as delayed neutrophil engraftment (6) and enhanced neutrophil 
activity and proliferation (9) but few reports have explained TGC immunotoxicity to lym-
phocytes and neutrophils. In this study, tigecycline showed no significant change in sple-
nocyte count at all three doses compared to the control group (as shown in Fig. 1), although 
the splenocyte count at 1X was lower than the control and the other treatments at the 
therapeutic dose.
Effect of TGC on delayed type hypersensitivity (DTH)
Alteration in leukocyte balance opens the possibility that the drug might have an ef-
fect on adaptive immunity, so we investigated the induction of DTH to confirm the TGC 
immunomodulatory effects. All doses of TGC showed an increase in the DTH response 24 h 
after secondary injection of antigen (SRBCs) in a dose-dependent manner. However, it 
was significant only when treated with the toxic 2X dose of TGC (p < 0.05) (Fig. 2). Induc-
tion of DTH reaction by TGC could be a result of the availability of factors responsible for 
the T cell maintenance and proliferation and those required for chemotaxis of macro-
phages (24). As there are no previous studies that investigated the effect of TGC on lym-
phocytes, the underlying mechanism of such effect is still unknown. Theoretically, the 
observed increase of footpad thickness and edema might be a response to increased mac-
rophages, DC and T-lymphocyte migration in addition to the proliferation of lymphocytes 
Fig. 3. The effect of tigecycline on anti-SRBCs antibody production assessed by hemagglutination ti-
ter. Data are mean ± SD, n = 7. Significant difference vs. control animals (NS): *p < 0.05; NS – normal 
saline; SRBC – sheep red blood cell; for dosing see Fig. 1.
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or antigen-antibody complex reaction at the footpad. This effect might lead to induction of 
an inflammatory response, which is associated with increased vascular permeability, im-
mune cell migration and edema.
Serum antibody hemagglutination (HA) titer
Hemagglutination titer is measured as agglutination of non-specific antibodies 
against sheep RBC (SRBC). The log2 of the highest dilution is used as the titer of the anti-
bodies. It shows the ability of lymphocytes to generate antibodies against non-specific 
SRBC antigens. Hemagglutination titer at the 2X dose (1428 µg kg–1 bm) showed significant 
reduction (p < 0.05) in the concentration of the anti-SRBC antibodies expressed as antibody 
titer (Fig. 3), whereas sub-therapeutic and therapeutic doses were unable to produce a 
significant change compared to the control (group I). Tigecycline significantly depressed 
the HA titer at 2X compared to the control. As antibodies are produced by B lymphocytes, 
which mature in the spleen, the reduction in antibody production compared to the control 
group is consistent with the reduction in lymphocytes in this study. Previous studies re-
ported varying impacts of TGC on adaptive immunity, with various experimental models. 
In vitro treatment of PBMCs with TGC and bacterial antigens reported an inhibitory activ-
ity on antibody production (13); yet another study, which used in vivo pneumonia murine, 
found that TGC did not alter antibody production (11). The reduction in peripheral lym-
phocytes, spleen cellularity and antibodyproduction are indicators of increased body’s 
susceptibility to infections as well as altered immunity.
Effect of TGC on splenocyte proliferation in vitro
Tigecycline achieves maximum blood concentration (cmax) of 1.5 µmol L–1 after a 50-mg 
i.v. twice-daily dose; however, it has a minimum inhibitory concentration (MIC) of 0.25–1 
mg L–1 (1–2 µmol L–1) against multidrug resistant bacteria in vitro (25). Therefore, higher 
doses are used clinically. In our study, splenocyte viability in vitro was significantly re-
Fig. 4. The effect of tigecycline on splenocyte proliferation in the MTT assay after 48-h treatment. 
Data are mean ± SD, n = 3. Significant difference vs. control (cells treated with NS): * p < 0.05; Con A 
– concanavalin A, NS – normal saline.
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duced after incubation with concentrations higher than 3.125 µmol L–1 of tigecycline for 48 
hours. TGC effectively inhibited the growth of splenocytes at concentrations above 1 µmol 
L–1 (p < 0.05). The IC50 value was 3.39 µmol L–1 with Con A and 2.92 µmol L–1 without Con 
A (Fig. 4). Increasing tigecycline concentration above IC50 showed an obvious reduction in 
splenocyte viability in vitro; this further complies with the in vivo results of decreased HA 
titer and altered splenocyte count at the 2X dose. When Con A-pretreated splenocytes were 
treated with 1.56 µmol L–1 of TGC (cmax of TGC from the pharmacokinetic study) or less, 
they significantly increased proliferation leading to a plateau, but not higher than the 
control cells (22). Although tigecycline is relatively safe at the regular dose (1X, 50 mg i.v. 
twice daily for humans), increasing the dose might be accompanied with alteration of the 
immune response and immune system components.
Effect of TGC on IL-17 and IL-2 release in Con A pretreated splenocytes
Interleukin-2 and IL-17 have a pronounced role in the non-specific immune response 
and T cell differentiation. IL-2 is a regulatory cytokine produced by Th-1 cells that activates 
Fig. 5. Proinflammatory cytokine secretion in response to tigecycline at concentrations of 12.5–0.195 
mmol L–1 in splenocytes pretreated with 2 mg mL–1 Con A: a) effect of TGC concentrations on IL-17; b) 
effect of TGC concentrations on IL-2 levels. Data is presented as mean ± SD (n = 3). Significant difference 
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macrophages against intracellular antigens (26), since it mediates acute inflammation and 
DTH (27). IL-17 is a proinflammatory cytokine produced by Th-17, neutrophils and mast 
cells and is required for Th-17 development (28). Th-17 cells were found to have some im-
munotoxic effects (27).
Due to the pronounced role of IL-2 and IL-17 in the non-specific immune response and 
T cell differentiation, we tested the effect of tigecycline on their release from splenocytes 
after pretreatment with Con A. A dose-dependent effect on the release of the tested cyto-
kines is shown in Fig. 5. Above IC50, the concentration of IL-2 increased significantly (Fig. 
5b, p < 0.001): at concentrations higher than 6.25 µmol L–1 by about 5 to 6 times, while IL-17 
significantly decreased (p < 0.05) at the same concentrations (Fig. 5a). Our results are con-
sistent with previous studies where tetracycline treatment induced IL-2 release (29). To the 
best of our knowledge, no previous studies investigated the release of IL-17 and IL-2 from 
splenocytes. Theoretically, naive CD4+ T cells differentiate into either Th-1 or Th-17 accord-
ing to the cytokines in the milieu and the present antigen by APCs. Enhanced release of 
IL-2 is known to suppress IL-4/Th-2 and promote the Th-1and Treg development. This 
increase in IL-2 could inhibit IL-17 and consequently Th-17 differentiation (30, 31). In vivo 
model of mouse pneumonia reported an inhibitory activity of TGC on IL-2; alteration of 
cytokine release and reduced cell viability provided further evidence of the immunomodu-
latory effects of tigecycline (11).
CONCLUSIONS
Although tigecycline was approved by the FDA for complicated infections in criti-
cally ill patients, its usage has been associated with increased mortality. As a new drug, 
investigation of the drug’s toxicity on the immune system and metabolic organs is of great 
importance. Our data showed that FDA-approved doses of tigecycline caused no toxicity 
to the metabolic and immunological functions. However, exceeding these doses would 
increase the potential immunomodulatory effects of TGC. Doubling of the dose caused 
alteration in adaptive immunity components as well as differential leukocytes in blood. It 
is worth considering the alteration that is exerted by the infection itself on the immune 
system. Therefore, further studies are needed to investigate the immunotoxicity of TGC in 
models of susceptible infections.
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